Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Homes and Hospitals of St Giles | OTHER |
| Alert Hospital, Ethiopia | OTHER |
| Armauer Hansen Research Institute, Ethiopia | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy
Objective: A randomised double blind controlled trial comparing Ciclosporin and Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the treatment of new Type 1 Reactions as Prednisolone.
We tested our hypothesis that ciclosporin would be as effective as prednisolone in the treatment of patients with leprosy reactions and nerve function impairment and that patients treated with ciclosporin would have fewer side effects than patients treated with prednisolone. A randomised controlled trial comparing ciclosporin and prednisolone in the treatment of acute leprosy T1R was conducted.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ciclosporin arm | Experimental | ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks) |
|
| prednisolone | Active Comparator | standard course of prednisolone given in a reducing regimen over 24 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ciclosporin | Drug | Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks) |
|
| Measure | Description | Time Frame |
|---|---|---|
| improvement in nerve function and Clinical Severity Score | at week 4, 20, 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events | up to 36 weeks | |
| Number of T1R recurrence episodes per patient in each treatment arm | up to 36 weeks | |
| Severity of T1R recurrence for patients in each treatment arm |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Diana Lockwood, MBChB | London School of Hygiene and Tropical Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alert Hospital | Addis Ababa | Ethiopia |
Not provided
| ID | Term |
|---|---|
| D007918 | Leprosy |
| ID | Term |
|---|---|
| D009165 | Mycobacterium Infections, Nontuberculous |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D016572 | Cyclosporine |
| D011239 | Prednisolone |
| D000305 | Adrenal Cortex Hormones |
| ID | Term |
|---|---|
| D003524 | Cyclosporins |
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Prednisolone | Drug | prednisolone 40mg daily then reducing regimen over 24 weeks |
|
|
| up to 36 weeks |
| extra prednisolone needed to control reaction | up to 36 weeks |
| 6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm | 36 weeks |
| Mean time to recurrence of T1R for patients in each treatment arm | up to 36 weeks |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D010455 |
| Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |